| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/22/2011 | DE102010012234A1 Pharmaceutical combination preparation, useful to treat cancer, preferably to reduce e.g. nephrotoxicity of cisplatin or platinum complex analog, comprises 12-imidazolyl-1-dodecanol and cisplatin or a platinum complex analog |
| 09/22/2011 | DE102010012232A1 New imidazole useful in pharmaceutical preparation e.g. for prevention or treatment of cancer diseases, pathological effects of alcohol misuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases |
| 09/22/2011 | DE102010012226A1 Pharmaceutical combination preparation, useful to improve the effect of ursodeoxycholic acid, which is useful to treat e.g. nonalcoholic-steatohepatitis and viral hepatitis, comprises 12-imidazolyl-1-dodecanol and ursodeoxycholic acid |
| 09/22/2011 | DE102010012224A1 Pharmaceutical preparation, useful for the intravenous treatment of paracetamol intoxication, comprises 12-imidazolyl-1-dodecanol or its salt |
| 09/22/2011 | DE102010012223A1 Pharmaceutical preparation, useful for the treatment of autoimmune disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Crohn's disease or ulcerative colitis, comprises 12-imidazolyl-1-dodecanol |
| 09/22/2011 | DE102010012199A1 Molekular geprägte Polymere für die Eliminierung von Metaboliten Molecularly imprinted polymers for the elimination of metabolites |
| 09/22/2011 | DE102010012183A1 Veresterte Polysaccharid-Osmotika Esterified polysaccharide osmotica |
| 09/22/2011 | DE102010012179A1 Vorrichtung für die Peritonealdialyse Apparatus for peritoneal dialysis |
| 09/22/2011 | DE102008037025B4 Kristalline Wirkstoff-Mikropartikel, Verfahren zu deren Herstellung und Verwendung in Arzneimitteln Crystalline drug microparticles, methods for their preparation and use in medicaments |
| 09/22/2011 | CA2797295A1 Ganglioside micelles as a delivery system for hidrophobic drugs |
| 09/22/2011 | CA2793657A1 Myeloid derived suppressor cell inhibiting agents |
| 09/22/2011 | CA2793641A1 Tosylate salt of cyclopropanecarboxylic acid 4-(6-chloro-3 -methyl-4,10-dihydro-3h-2,3,4,9-tetrabenzo[f]azulene-9-carbonyl)-2-fluorobenzylamide |
| 09/22/2011 | CA2793594A1 Method and process for preparation and production of deuterated .omega.-diphenylurea |
| 09/22/2011 | CA2793527A1 Novel methods for targeting cancer stem cells |
| 09/22/2011 | CA2793526A1 Novel compounds and compositions for targeting cancer stem cells |
| 09/22/2011 | CA2793525A1 Method for improving dissolution of anticoagulant agent |
| 09/22/2011 | CA2793523A1 Cyclopropanecarboxylic acid derivative |
| 09/22/2011 | CA2793413A1 Crystal form of edoxaban tosylate monohydrate and method of producing same |
| 09/22/2011 | CA2793392A1 Pyridine and pyrazine derivative for the treatment of cf |
| 09/22/2011 | CA2793391A1 Arylsulfonamide ccr3 antagonists |
| 09/22/2011 | CA2793373A1 Cleavable modifications to reducible poly (amido ethylenimines)s to enhance nucleotide delivery |
| 09/22/2011 | CA2793359A1 Process for the preparation of malic acid salt of sunitinib |
| 09/22/2011 | CA2793324A1 A substituted pyrimidine as a prostaglandin d2 receptor antagonist |
| 09/22/2011 | CA2793311A1 Modulators of hec1 activity and methods therefor |
| 09/22/2011 | CA2793299A1 Morpholinylquinazolines |
| 09/22/2011 | CA2793279A1 Imidazopyrazines |
| 09/22/2011 | CA2793223A1 Substituted pyrimidines as prostaglandin d2 receptor antagonists |
| 09/22/2011 | CA2793170A1 Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport |
| 09/22/2011 | CA2793125A1 New enzyme inhibitor compounds |
| 09/22/2011 | CA2793086A1 Anti-infective compounds |
| 09/22/2011 | CA2793024A1 Imidazopyridine compounds, compositions and methods of use |
| 09/22/2011 | CA2793023A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 09/22/2011 | CA2792696A1 Modified u7 snrnas for treatment of neuromuscular diseases |
| 09/22/2011 | CA2792430A1 Agomelatine hydrobromide hydrate and preparation thereof |
| 09/22/2011 | CA2792417A1 Agomelatine hydrochloride hydrate and preparation thereof |
| 09/22/2011 | CA2792234A1 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
| 09/22/2011 | CA2792207A1 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 09/22/2011 | CA2791737A1 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| 09/22/2011 | CA2791613A1 Indazole compounds and their uses |
| 09/22/2011 | CA2791505A1 Cycloalkyl-substituted imidazole derivative |
| 09/22/2011 | CA2791389A1 Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use |
| 09/22/2011 | CA2791281A1 Spiro-tetracyclic ring compounds as beta-secretase modulators |
| 09/22/2011 | CA2791081A1 Treatment for pulmonary hypertension |
| 09/22/2011 | CA2790605A1 Inhibitors of glycogen synthase kinase 3 for use in therapeutic methods and screening method relating thereto |
| 09/22/2011 | CA2790408A1 Risperidone immunoassay |
| 09/22/2011 | CA2790183A1 Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use |
| 09/22/2011 | CA2788060A1 Pharmaceutical composition for treatment of increased intraocular pressure |
| 09/22/2011 | CA2769715A1 Microbially-stable vitamin e solutions |
| 09/22/2011 | CA2697564A1 Use of the clopidogrel with asa for the preparation of a medicament for use in the prevention of major vascular events |
| 09/21/2011 | EP2366706A1 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 09/21/2011 | EP2366702A1 New oxadiazole derivatives |
| 09/21/2011 | EP2366701A1 Acenaphtho heterocycle compounds, cyclodextrin inclusion compounds and complexes, and uses in the manufactures of bh3 protein analogue, bcl-2 family protein inhibitors thereof |
| 09/21/2011 | EP2366699A1 8-substituted isoquinoline derivative and use thereof |
| 09/21/2011 | EP2366698A1 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| 09/21/2011 | EP2366697A1 Guanidine compounds and use of same as binding partners for 5-HT5 receptors |
| 09/21/2011 | EP2366695A1 A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| 09/21/2011 | EP2366691A1 The nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof |
| 09/21/2011 | EP2366690A1 Salts and crystalline salt forms of an 2-indolinone derivative |
| 09/21/2011 | EP2366689A1 Saccharin salts and crystalline salt forms of an 2-indolinone derivative |
| 09/21/2011 | EP2366688A1 Salts and crystalline salt forms of an 2-indolinone derivative |
| 09/21/2011 | EP2366687A2 Benzenesulfonamide derivatives and pharmaceutical composition thereof |
| 09/21/2011 | EP2366684A1 New compounds of the pterocarpanquinone family, method for preparing the same, pharmaceutical composition containing the new compounds of the pterocarpanquinone family, uses and therapeutic method |
| 09/21/2011 | EP2366432A1 Inhibitors of glycogen synthase kinase 3 for use in therapeutic methods and screening method relating thereto |
| 09/21/2011 | EP2366431A1 Myeloperoxidase as a target in atrial fibrillation |
| 09/21/2011 | EP2366408A1 Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation |
| 09/21/2011 | EP2366399A1 Non-cytotoxic protein conjugates |
| 09/21/2011 | EP2366398A1 Cancer therapy with a parvovirus combined with an HDAC inhibitor |
| 09/21/2011 | EP2366397A1 Intravascular indwelling catheter lock solution containing acetic acid and container containing the same |
| 09/21/2011 | EP2366396A1 Myocardial perfusion imaging using adenosine receptor agonists |
| 09/21/2011 | EP2366395A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis |
| 09/21/2011 | EP2366394A1 Characterization and validation of inhibitors and ligands of dipeptidyl aminopeptidase IV (DP IV) |
| 09/21/2011 | EP2366393A2 Roflumilast for the treatment of pulmonary hypertension |
| 09/21/2011 | EP2366392A1 Guanidine compounds and use of same as binding partners for 5-HT5 receptors |
| 09/21/2011 | EP2366391A2 Anti-inflammatory agents |
| 09/21/2011 | EP2366390A2 Anti-inflammatory agents |
| 09/21/2011 | EP2366389A1 Severe sepsis preventive therapeutic agent |
| 09/21/2011 | EP2366388A1 Non-occlusive transdermal therapeutic system for administering buprenorphine |
| 09/21/2011 | EP2366381A1 Phenylephrine pharmaceutical formulations and compositions for colonic absorption |
| 09/21/2011 | EP2366380A1 Extended release formulation containing a wax |
| 09/21/2011 | EP2366379A1 Cefdinir formulation with improved dissolution rate |
| 09/21/2011 | EP2365977A1 A triazolothiadiazole inhibitor of c-met protein kinase |
| 09/21/2011 | EP2365976A1 Gamma secretase modulators |
| 09/21/2011 | EP2365975A1 Imidazopyridine derivatives which inhibit the secretion of gastric acid |
| 09/21/2011 | EP2365974A1 Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same |
| 09/21/2011 | EP2365973A1 Gamma secretase modulators |
| 09/21/2011 | EP2365972A1 Modulators of atp-binding cassette transporters |
| 09/21/2011 | EP2365971A1 Benzimidazole derivates and their use for modulating the gabaa, receptor complex |
| 09/21/2011 | EP2365970A1 Pyridazinones and their use as btk inhibitors |
| 09/21/2011 | EP2365969A1 Novel anti-biofilm agents |
| 09/21/2011 | EP2365965A1 Process for manufacturing substituted 3-pyridylmethyl ammonium bromides |
| 09/21/2011 | EP2365956A2 Long acting conserved natural functional groups curcumin |
| 09/21/2011 | EP2365955A1 Aryl di-substituted propenone compounds |
| 09/21/2011 | EP2365908A2 Substrates providing multiple releases of active agents |
| 09/21/2011 | EP2365837A2 Systems and methods for treatment of aneurysms using zinc chelator(s) |
| 09/21/2011 | EP2365829A1 Combination of an oxidant and a photoactivator for the healing of wounds |
| 09/21/2011 | EP2365827A1 Fully human influenza m2 specific antibodies |
| 09/21/2011 | EP2365814A1 Modulation of toll-like receptor 4 expression by antisense oligonucleotides |
| 09/21/2011 | EP2365813A2 Methods of reducing the risk of cardiovascular disease in postmenopausal women |
| 09/21/2011 | EP2365812A1 Pharmaceutical formulations for iontophoretic delivery of a corticosteroid |
| 09/21/2011 | EP2365811A1 A method for contraception |